

SYNNESTVEDT & LACHNER LLP

Art Unit 1652

Application No. 09/277,401

June 12, 2003

Attorney Docket No. P 22,944-C USA

Page 2

Amendments to the Claims

All cancelled claims are cancelled without prejudice.

Claims 1 to 14 (Cancelled)

15. (Original) A composition capable of lowering the expression of LIPG in a patient comprising a ribozyme.

16. (Original) The composition of Claim 15 comprising an expression vector including a DNA sequence encoding said ribozyme.

Claims 17 to 21 (Cancelled)

22. (Original) A composition for increasing the enzymatic activity of LIPG polypeptide in a patient comprising an enhancer which binds to and enhances the enzymatic activity of the LIPG polypeptide.

23. (Original) A method for raising the level of high density lipoprotein (HDL) cholesterol and apolipoprotein AI in a patient comprising administering to said patient a composition which lowers the enzymatic activity of LIPG in said patient.

Claims 24 to 43 (Cancelled)

44. (Original) The method of Claim 23 further comprising administration of a

SYNNESTVEDT & LECHNER LLP

Art Unit 1652

Application No. 09/277,401

June 12, 2003

Attorney Docket No. P 22,944-C USA

Page 3

composition capable of expressing apolipoprotein AI in said patient.

Claims 45 to 56 (Cancelled)

57. (Original) A method for lowering the level of LDL cholesterol in a patient comprising administering to the patient an enhancer which preferentially enhances the enzymatic reactions between LIPG polypeptide and LDL cholesterol relative to the enzymatic reactions between LIPG polypeptide and HDL cholesterol and apolipoprotein AI.

41
58. (Original) A method for lowering the level of VLDL cholesterol in a patient comprising administering to the patient an enhancer which preferentially enhances the enzymatic reactions between LIPG polypeptide and VLDL cholesterol relative to the enzymatic reactions between LIPG polypeptide and HDL cholesterol and apolipoprotein AI.

59. (Original) A method for diagnosing a predisposition to low HDL cholesterol and apolipoprotein AI levels comprising obtaining a tissue sample from a patient and measuring the level of LIPG polypeptide in said sample.

Claims 60 to 62 (Cancelled)

63. (Original) A method for determining whether a test compound can inhibit the enzymatic reaction between the LIPG polypeptide and HDL cholesterol and apolipoprotein AI comprising: (A) comparing the level of HDL cholesterol and apolipoprotein AI in a first sample comprising: (1) HDL cholesterol and apolipoprotein AI, (2) LIPG polypeptide, and (3) said test compound with the

SYNNESTVEDT & LECHNER LLP

Art Unit 1652

Application No. 09/277,401

June 12, 2003

Attorney Docket No. P 22,944-C USA

Page 4

level of HDL cholesterol and apolipoprotein AI in another sample comprising: (4) HDL cholesterol and apolipoprotein AI, and (5) LIPG polypeptide; and (B) identifying whether or not said test compound is effective in inhibiting the enzymatic reaction between the LIPG polypeptide and HDL cholesterol and apolipoprotein AI by observing whether or not the first sample has a higher level of HDL cholesterol and apolipoprotein AI than that of said other sample.

64. (Original) A method for determining whether a test compound can enhance the enzymatic reaction between the LIPG polypeptide and VLDL cholesterol comprising: (A) comparing the level of VLDL cholesterol in a first sample comprising: (1) VLDL cholesterol, (2) LIPG polypeptide, and (3) said test compound with the level of VLDL cholesterol in another sample comprising: (4) VLDL cholesterol, and (5) LIPG polypeptide; and (B) identifying whether or not said test compound is effective in enhancing the enzymatic reaction between the LIPG polypeptide and VLDL cholesterol by observing whether or not the first sample has a lower level of VLDL cholesterol than that of said other sample.
65. (Original) A method for determining whether a test compound can enhance the enzymatic reaction between the LIPG polypeptide and LDL cholesterol comprising: (A) comparing the level of LDL cholesterol in a first sample comprising: (1) LDL cholesterol, (2) LIPG polypeptide, and (3) said test compound with the level of LDL cholesterol in another sample comprising: (4) LDL cholesterol, and (5) LIPG polypeptide; and (B) identifying whether or not said test compound is effective in enhancing the enzymatic reaction between the LIPG polypeptide and LDL cholesterol by observing whether or not the first sample has a lower level of LDL cholesterol than that of said other sample.

SYNNESTVEDT & LIECHNER LLP

Art Unit 1652

Application No. 09/277,401

June 12, 2003

Attorney Docket No. P 22,944-C USA

Page 5

Claims 66 to 97 (Cancelled)